Antiretroviral therapy 2010 update: Current practices and controversies

Archives of Pharmacal Research

Volumn 34, Issue 7, 2011, Pages 1045-1053

  Grant, Matthew ^a   Samuel, Rafik ^a   Bettiker, Robert L ^a   Suh, Byungse ^a  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

Acquired immune deficiency syndrome (AIDS); Antiretroviral therapy; HIV

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; AMPRENAVIR; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYTOCHROME P450 3A4; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HLA B ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARAVIROC; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FATIGUE; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MORTALITY; NAUSEA; PATIENT CARE; RASH; REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 80052324078     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-011-0701-3     Document Type: Review

References (43)

1. Bedimo, R., Westfall, A., Drechsler, H., and Tebas, P., Abacavir use and risk of myocardial infraction and cerebrovascular disease in the HAART era. In International AIDS Society conference on HIV Pathogenesis, Treatment and Prevention. Capetown: Abstract MOAB202, (2009).
2. Z. L. Brumme J. Goodrich H. B. Mayer C. J. Brumme B. M. Henrick B. Wynhoven J. J. Asselin P. K. Cheung R. S. Hogg J. S. Montaner P. R. Harrigan 2005 Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals J. Infect. Dis. 192 466 474 15995960 10.1086/431519 1:CAS:528:DC%2BD2MXot1Gjs7s%3D (Pubitemid 41023125)
3. Cohen, C., Molina, J. M., Cahn, P., Clotet, B., Fourie, J., Grinsztejn, B., Hao, W., Johnson, M., Saag, M., Supparatpinyo, K., Crauwels, H., Rimsky, L., Vanveggel, S., Williams, P., and Boven, K., Pooled week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised, phase III trials comparing TMC278 versus efavirenz in treatment-naive, HIV-1-infected patients. In XVIII International AIDS Conference. Vienna, Austria: Oral Abstract THLBB206, (2010a).
4. Cohen, C., Shamblaw, D., Ruane, P., Rlion, R., DeJesus, E., Liu, H., Zhong, L., Warren, D., Kearney, B., and Chuck, S., Single-tablet, fixed-dose regimen of elvitegravir/emtricitabine/tenofovir disoproxil fumarate/GS-9350 achieves a high rate of virologic suppression and GS-9350 is an effective booster. In 17th Conference on Retroviruses and Opportunistic Infections. San Francisco: Oral Abstract 58, (2010b).
5. D. A. Cooper J. Heera J. Goodrich M. Tawadrous M. Saag E. Dejesus N. Clumeck S. Walmsley N. Ting E. Coakley J. D. Reeves G. Reyes-Teran M. Westby E. Van Der Ryst P. Ive L. Mohapi H. Mingrone A. Horban F. Hackman J. Sullivan H. Mayer 2010 Maraviroc versus efavirenz, both in combination with zidovudinelamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection J. Infect. Dis. 201 803 813 20151839 10.1086/650697 1:CAS:528:DC%2BC3cXkslSlt7Y%3D
6. Daar, E., Tierney, C., Fischl, M., Collier, A., Mollan, K., Budhathoki, C., Godfrey, C., Jahed, N., Katzenstein, D., Sax, P., and the ACTG A5202 Study Team, ACTG 5202: Final results of ABC/3TC or TDF/FTC with either EFV or ATV/r in treatment-naive HIV-infected patients. In 17th Conference on Retroviruses and Opportunistic Infections. San Francisco: Oral Abstract 59, (2010).
7. M. P. Dubé D. L. Johnson J. S. Currier J. M. Leedom 1997 Protease inhibitor-associated hyperglycaemia Lancet 350 713 714 9291911 10.1016/S0140-6736(05)63513-1 (Pubitemid 127739261)
8. W. M. El-Sadr J. D. Lundgren J. D. Neaton F. Gordin D. Abrams R. C. Arduino A. Babiker W. Burman N. Clumeck C. J. Cohen D. Cohn D. Cooper J. Darbyshire S. Emery G. Fätkenheuer B. Gazzard B. Grund J. Hoy K. Klingman M. Losso N. Markowitz J. Neuhaus A. Phillips C. Rappoport the Strategies for Management of Antiretroviral Therapy 2006 CD4+ count-guided interruption of antiretroviral treatment N. Engl. J. Med. 355 2283 2296 17135583 10.1056/NEJMoa062360 1:STN:280:DC%2BD28npvVSntw%3D%3D (Pubitemid 44837777)
9. N. Friis-Møller C. A. Sabin R. Weber A. d'Arminio Monforte W. M. El-Sadr P. Reiss R. Thiébaut L. Morfeldt S. De Wit C. Pradier G. Calvo M. G. Law O. Kirk A. N. Phillips J. D. Lundgren the Data Collection on Adverse Events of Anti-HIV Drugs 2003 Combination antiretroviral therapy and the risk of myocardial infarction N. Engl. J. Med. 349 1993 2003 14627784 10.1056/NEJMoa030218 (Pubitemid 37448922)
10. L. Garvey A. Winston 2009 Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor Expert Opin. Investig. Drugs 18 1035 1041 19548857 10.1517/13543780903055056 1:CAS:528:DC%2BD1MXns1erurc%3D
11. R. M. Gulick J. Lalezari J. Goodrich N. Clumeck E. DeJesus A. Horban J. Nadler B. Clotet A. Karlsson M. Wohlfeiler J. B. Montana M. McHale J. Sullivan C. Ridgway S. Felstead M. W. Dunne E. van der Ryst H. Mayer the MOTIVATE Study Teams 2008 Maraviroc for previously treated patients with R5 HIV-1 infection N. Engl. J. Med. 359 1429 1441 18832244 10.1056/NEJMoa0803152 1:CAS:528: DC%2BD1cXhtFOktLbM
12. R. G. Hewitt 2002 Abacavir hypersensitivity reaction Clin. Infect. Dis. 34 1137 1142 11915004 10.1086/339751 1:CAS:528:DC%2BD38XjsFyitr8%3D (Pubitemid 34289688)
13. C. Hicks R. M. Gulick 2009 Raltegravir: the first HIV type 1 integrase inhibitor Clin. Infect. Dis. 48 931 939 19231980 10.1086/597290 1:CAS:528:DC%2BD1MXksFalsb4%3D
14. A. Hsu G. R. Granneman R. J. Bertz 1998 Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents Clin. Pharmacokinet. 35 275 291 9812178 10.2165/00003088-199835040-00002 1:CAS:528:DyaK1cXnsVWrsrY%3D (Pubitemid 28491214)
15. L. B. Johnson L. D. Saravolatz 2009 Etravirine, a nextgeneration nonnucleoside reverse-transcriptase inhibitor Clin. Infect. Dis. 48 1123 1128 19275497 10.1086/597469 1:CAS:528:DC%2BD1MXltFektL0%3D
16. C. Katlama R. Haubrich J. Lalezari A. Lazzarin J. V. Madruga J. M. Molina M. Schechter M. Peeters G. Picchio J. Vingerhoets B. Woodfall G. De Smedt the DUET-1DUET-2 study groups 2009 Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials AIDS 23 2289 2300 19710593 10.1097/QAD. 0b013e3283316a5e 1:CAS:528:DC%2BD1MXhtlensrjJ
17. J. M. Kilby J. J. Eron 2003 Novel therapies based on mechanisms of HIV-1 cell entry N. Engl. J. Med. 348 2228 2238 12773651 10.1056/NEJMra022812 1:CAS:528:DC%2BD3sXktVCqs78%3D (Pubitemid 36618135)
18. M. M. Kitahata S. J. Gange A. G. Abraham B. Merriman M. S. Saag A. C. Justice R. S. Hogg S. G. Deeks J. J. Eron J. T. Brooks S. B. Rourke M. J. Gill R. J. Bosch J. N. Martin M. B. Klein L. P. Jacobson B. Rodriguez T. R. Sterling G. D. Kirk S. Napravnik A. R. Rachlis L. M. Calzavara M. A. Horberg M. J. Silverberg K. A. Gebo J. J. Goedert C. A. Benson A. C. Collier S. E. Van Rompaey H. M. Crane R. G. McKaig B. Lau A. M. Freeman R. D. Moore the NA-ACCORD Investigators 2009 Effect of early versus deferred antiretroviral therapy for HIV on survival N. Engl. J. Med. 360 1815 1826 19339714 10.1056/NEJMoa0807252 1:CAS:528:DC%2BD1MXlsVGmtrY%3D
19. J. L. Lennox E. DeJesus A. Lazzarin R. B. Pollard J. V. Madruga D. S. Berger J. Zhao X. Xu A. Williams-Diaz A. J. Rodgers R. J. Barnard M. D. Miller M. J. DiNubile B. Y. Nguyen R. Leavitt P. Sklar the STARTMRK investigators 2009 Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial Lancet 374 796 806 19647866 10.1016/S0140-6736(09)60918-1 1:CAS:528:DC%2BD1MXhtV2ksLnL
20. R. D. MacArthur R. M. Novak 2008 Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents Clin. Infect. Dis. 47 236 241 18532888 10.1086/589289 1:CAS:528:DC%2BD1cXoslWgu78%3D (Pubitemid 351920626)
21. S. Mallal E. Phillips G. Carosi J. M. Molina C. Workman J. Tomazic E. Jägel-Guedes S. Rugina O. Kozyrev J. F. Cid P. Hay D. Nolan S. Hughes A. Hughes S. Ryan N. Fitch D. Thorborn A. Benbow the PREDICT-1 Study Team 2008 HLA-B*5701 screening for hypersensitivity to abacavir N. Engl. J. Med. 358 568 579 18256392 10.1056/NEJMoa0706135 (Pubitemid 351214284)
22. Mathias, A., Lee, M., Callebaut, C., Xu, L., Tsai, L., Burray, B., Liu, H., Yale, K., Warren, D., and Kearney, B., GS-9350: A pharmacoenhancer without anti-HIV activity. In 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada: Oral Abstract 40, (2009).
23. K. McKeage C. M. Perry S. J. Keam 2009 Darunavir: a review of its use in the management of HIV infection in adults Drugs 69 477 503 19323590 10.2165/00003495-200969040-00007 1:CAS:528:DC%2BD1MXmtFelsL8%3D
24. A. M. Mills M. Nelson D. Jayaweera K. Ruxrungtham I. Cassetti P. M. Girard C. Workman I. Dierynck V. Sekar C. V. Abeele L. Lavreys 2009 Once-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis AIDS 23 1679 1688 19487905 10.1097/QAD. 0b013e32832d7350 1:CAS:528:DC%2BD1MXpvV2gtbg%3D
25. J. M. Molina J. Andrade-Villanueva J. Echevarria P. Chetchotisakd J. Corral N. David G. Moyle M. Mancini L. Percival R. Yang V. Wirtz M. Lataillade J. Absalon D. McGrath the CASTLE Study Team 2010 Oncedaily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study J. Acquir. Immune Defic. Syndr. 53 323 332 20032785 10.1097/QAI. 0b013e3181c990bf 1:CAS:528:DC%2BC3cXisFejur8%3D
26. K. Mulligan C. Grunfeld V. W. Tai H. Algren M. Pang D. N. Chernoff J. C. Lo M. Schambelan 2000 Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection J. Acquir. Immune Defic. Syndr. 23 35 43 10708054 10.1097/00042560-200001010-00005 1:CAS:528:DC%2BD3cXktlGrtrw%3D (Pubitemid 30123263)
27. M. A. Noor T. Seneviratne F. T. Aweeka J. C. Lo J. M. Schwarz K. Mulligan M. Schambelan C. Grunfeld 2002 Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study AIDS 16 F1 F8 11964551 10.1097/00002030-200203290-00002 (Pubitemid 34274457)
28. C. Orkin S. T. Sadiq L. Rice F. Jackson the UK EPI team 2010 Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-Bz.ast;5701 in HIV-1-infected UK subjects HIV Med. 11 187 192 19780860 10.1111/j.1468-1293.2009.00762.x 1:STN:280:DC%2BC3c7ktVyntA%3D%3D
29. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 1-161 (2009).
30. Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States, 1-90 (2009).
31. S. A. Riddler R. Haubrich A. G. DiRienzo L. Peeples W. G. Powderly K. L. Klingman K. W. Garren T. George J. F. Rooney B. Brizz U. G. Lalloo R. L. Murphy S. Swindells D. Havlir J. W. Mellors the AIDS Clinical Trials Group Study A5142 Team 2008 Class-sparing regimens for initial treatment of HIV-1 infection N. Engl. J. Med. 358 2095 2106 18480202 10.1056/NEJMoa074609 1:CAS:528: DC%2BD1cXlvFCktb8%3D (Pubitemid 351679596)
32. M. Saag J. Goodrich G. Fätkenheuer B. Clotet N. Clumeck J. Sullivan M. Westby E. van der Ryst H. Mayer the A4001029 Study Group 2009 A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1 J. Infect. Dis. 199 1638 1647 19432546 10.1086/598965 1:CAS:528:DC%2BD1MXmvVOmurw%3D
33. C. A. Sabin S. W. Worm R. Weber P. Reiss W. El-Sadr F. Dabis S. De Wit M. Law A. D'Arminio Monforte N. Friis-Møller O. Kirk C. Pradier I. Weller A. N. Phillips J. D. Lundgren the D:A:D Study Group 2008 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration Lancet 371 1417 1426 18387667 10.1016/S0140-6736(08)60423-7 1:CAS:528: DC%2BD1cXlsFCisL8%3D
34. R. Samuel R. L. Bettiker B. Suh 2006 Antiretroviral therapy 2006: pharmacology, applications, and special situations Arch. Pharm. Res. 29 431 458 16833010 10.1007/BF02969415 1:CAS:528:DC%2BD28XntFGnu70%3D (Pubitemid 44087020)
35. J. R. Santos J. M. Llibre E. Ferrer P. Domingo A. Imaz J. Moltó R. Martin-Iguacel C. Caum D. Podzamczer B. Clotet 2009 Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression HIV Clin. Trials 10 432 438 20133273 10.1310/hct1006-432
36. P. E. Sax C. Tierney A. C. Collier M. A. Fischl K. Mollan L. Peeples C. Godfrey N. C. Jahed L. Myers D. Katzenstein A. Farajallah J. F. Rooney B. Ha W. C. Woodward S. L. Koletar V. A. Johnson P. J. Geiseler E. S. Daar the AIDS Clinical Trials Group Study A5202 Team 2009 Abacavir-lamivudine versus tenofoviremtricitabine for initial HIV-1 therapy N. Engl. J. Med. 361 2230 2240 19952143 10.1056/NEJMoa0906768 1:CAS:528:DC%2BD1MXhsFWhsb%2FI
37. D. H. Shepp R. C. Stevens 2005 Ritonavir boosting of HIV protease inhibitors Antibiotics for Clinicians 9 301 311
38. K. Y. Smith P. Patel D. Fine N. Bellos L. Sloan P. Lackey P. N. Kumar D. H. Sutherland-Phillips C. Vavro L. Yau P. Wannamaker M. S. Shaefer the HEAT Study Team 2009 Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment AIDS 23 1547 1556 19542866 10.1097/QAD.0b013e32832cbcc2 1:CAS:528:DC%2BD1MXovVSgs7c%3D
39. R. T. Steigbigel D. A. Cooper P. N. Kumar J. E. Eron M. Schechter M. Markowitz M. R. Loutfy J. L. Lennox J. M. Gatell J. K. Rockstroh C. Katlama P. Yeni A. Lazzarin B. Clotet J. Zhao J. Chen D. M. Ryan R. R. Rhodes J. A. Killar L. R. Gilde K. M. Strohmaier A. R. Meibohm M. D. Miller D. J. Hazuda M. L. Nessly M. J. DiNubile R. D. Isaacs B. Y. Nguyen H. Teppler the BENCHMRK Study Teams 2008 Raltegravir with optimized background therapy for resistant HIV-1 infection N. Engl. J. Med. 359 339 354 18650512 10.1056/NEJMoa0708975
40. I. Sudano L. E. Spieker G. Noll R. Corti R. Weber T. F. Lüscher 2006 Cardiovascular disease in HIV infection Am. Heart J. 151 1147 1155 16781213 10.1016/j.ahj.2005.07.030 (Pubitemid 44172869)
41. M. A. Thompson J. A. Aberg P. Cahn J. S. Montaner G. Rizzardini A. Telenti J. M. Gatell H. F. Günthard S. M. Hammer M. S. Hirsch D. M. Jacobsen P. Reiss D. D. Richman P. A. Volberding P. Yeni R. T. Schooley International AIDS Society-USA 2010 Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel JAMA 304 321 333 20639566 10.1001/jama.2010.1004 1:CAS:528:DC%2BC3cXpt1Sgs78%3D
42. J. Vingerhoets L. Tambuyzer H. Azijn A. Hoogstoel S. Nijs M. Peeters M. P. de Béthune G. De Smedt B. Woodfall G. Picchio 2010 Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies AIDS 24 503 514 20051805 10.1097/QAD.0b013e32833677ac 1:CAS:528:DC%2BC3cXisFOjur4%3D
43. S. W. Worm C. Sabin R. Weber P. Reiss W. El-Sadr F. Dabis S. De Wit M. Law A. D. Monforte N. Friis-Møller O. Kirk E. Fontas I. Weller A. Phillips J. Lundgren 2010 Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study J. Infect. Dis. 201 318 330 20039804 10.1086/649897 1:CAS:528: DC%2BC3cXisFGqtLY%3D